Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Ugur Akar"'
Autor:
Ibrahim Tekedereli, S Neslihan Alpay, Ugur Akar, Erkan Yuca, Cristian Ayugo-Rodriguez, He-Dong Han, Anil K Sood, Gabriel Lopez-Berestein, Bulent Ozpolat
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powe
Externí odkaz:
https://doaj.org/article/491a4bca1ba8498ca5d9ccce4c1c55fb
Autor:
Naoto T. Ueno, Gabriel N. Hortobagyi, Rene Nieves-Alicea, Tiffany A. LaFortune, Banu K. Arun, Ugur Akar, Ana M. Tari, Dongwei Zhang
Supplementary Figures 1 and 2 from Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0472c06566dce5b8c35b970d4efba1da
https://doi.org/10.1158/1535-7163.22485030
https://doi.org/10.1158/1535-7163.22485030
Autor:
Naoto T. Ueno, Gabriel N. Hortobagyi, Rene Nieves-Alicea, Tiffany A. LaFortune, Banu K. Arun, Ugur Akar, Ana M. Tari, Dongwei Zhang
The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03600eeca050b47520ad10b9d1909ebc
https://doi.org/10.1158/1535-7163.c.6531732.v1
https://doi.org/10.1158/1535-7163.c.6531732.v1
Publikováno v:
Journal of Environmental Pathology, Toxicology and Oncology. 38:13-20
All-trans-retinoic acid (ATRA) is a potent inducer of cellular differentiation, growth arrest, and apoptosis as well as a front-line therapy for acute promyelocytic leukemia (APL). The present study provides evidence that induction of autophagy is re
Publikováno v:
International Journal of Oncology
PARP inhibitors are considered promising anti-cancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects
Autor:
Gn. Hortobagyi, Jennifer K. Litton, Constance Albarracin, Ugur Akar, Angelica M. Gutierrez-Barrera, A. M. Gonzalez-Angulo, Banu Arun
Publikováno v:
Cancer Research. 70:P6-10
Background: Triple-negative breast cancer (TNBC) affects 10-17% of all breast cancers and is associated with a poor prognosis. The biology of TNBC is poorly understood; however, it has been shown that up to 60% of BRCA1 mutation carriers develop TNBC
Autor:
Ana M. Tari, Gabriel N. Hortobagyi, René Nieves-Alicea, Tiffany A. LaFortune, Dongwei Zhang, Ugur Akar, Naoto T. Ueno, Banu Arun
Publikováno v:
Molecular Cancer Therapeutics. 9:3090-3099
The epidermal growth factor receptor (EGFR) signaling pathway has emerged as a promising target for cancer therapy. EGFR tyrosine kinase inhibitors (TKI) such as erlotinib have been approved for cancer treatment but have shown very limited activity i
Autor:
Pablo E. Vivas-Mejia, Marian Acevedo-Alvarez, Bulent Ozpolat, Gabriel Lopez-Berestein, Isabel Zorrilla-Calancha, Ugur Akar
Publikováno v:
Apoptosis. 13:915-928
All-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) induce differentiation and apoptosis in acute promyelocytic leukemia (APL) cells. Here we investigated the role and regulation of death-associated protein-5 (DAP5/p97/NAT1), a novel inhibitor
Publikováno v:
Molecular Cancer Research. 5:241-249
Elevated expression of tissue transglutaminase (TG2) in cancer cells has been implicated in the development of drug resistance and metastatic phenotypes. However, the role and the mechanisms that regulate TG2 expression remain elusive. Here, we provi
Publikováno v:
Pathology & Oncology Research. 11:22-25
Inherited polymorphisms in the genes controlling the cell cycle or functioning in the DNA repair mechanisms may impair their function and contribute to genetic susceptibility. Abnormalities in the DNA repair have been reported in head and neck cancer